Alteration of $p53$ and $p21$ during hepatocarcinogenesis in tree shrews

Jian-Jia Su, Ke-Chen Ban, Yuan Li, Liu-Liang Qin, Hui-Yun Wang, Chun Yang, Chao Ou, Xiao-Xian Duan, Young-Lk Lee, Rui-Qi Yang

Jian-Jia Su, Yuan Li, Ke-Chen Ban, Liu-Liang Qin, Chun Yang, Chao Ou, Xiao-Xian Duan, Department of Experimental Pathology, Guangxi Cancer Institute, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Hui-Yun Wang, Rui-Qi Yang, Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China

Young-Lk Lee, Bioscience Research Division, Korea Research Institute of Bioscience and Biotechnology, South Korea

Supported by the National Natural Science Foundation of China, No. 39260033 and Natural Science Foundation of Guangxi, No. 0143058

Institute of Bioscience and Biotechnology, South Korea

Correspondence to: Professor Jian-Jia Su, Department of Experimental Pathology, Guangxi Cancer Institute, Nanning 530021, Guangxi Zhuang Autonomous Region, China. jianjiasu2002@yahoo.com

Fax: +86-771-5312000

Telephone: +86-771-5331100

Fax: +86-771-5312000

Received: 2003-10-31 Accepted: 2004-01-12

Abstract

AIM: To investigate $p53$ mutation and $p21$ expression in hepatocarcinogenesis induced by hepatitis B virus (HBV) and aflatoxin B1 (AFB1) in tree shrews, and to reveal the role of these genes in hepatocarcinogenesis.

METHODS: Tree shrews were divided into four groups: group A, those infected with HBV and fed with AFB1 ($n = 39$); group B, those infected with HBV alone ($n = 28$); group C, those fed with AFB1, alone ($n = 29$); and group D, normal controls ($n = 20$). The tree shrews underwent liver biopsies once every 15 wk. Expression of $p53$ and $p21$ proteins and genes in the biopsies and tumor tissues of the experimental tree shrews was detected, respectively, by immunohistochemistry, and by Southern blotting and reverse transcription-polymerase chain reaction and sequencing.

RESULTS: The incidence of hepatocellular carcinomas (HCC) was higher in group A (66.7%) than that in group B (35.7%) and C (30%). The time of HCC occurrence was also earlier in group A than that in group C (120.8±16.6 wk vs 153.3±5.8 wk, respectively, $P < 0.01$). $p53$ protein was not detected by immunohistochemistry in all groups before the 75th wk of the experiment. At the 105th wk, the positive rates for $p53$ were 78.6%, 60% and 71.4% in groups B, A and C, respectively, which were significantly higher than that in group D (10%) (all $P < 0.05$). An abnormal band of $p53$ gene was observed in groups A and C. The mutation points of $p53$ gene in tree shrews with HCC were at codons 275, 78 and 13. The nucleotide sequence and amino acid sequence of tree shrew's wild-type p53 showed 91.7% and 93.4% homologies with those of human p53, respectively. The immunopositivity for $p21$ was found before HCC development. The incidence of HCC was significantly higher in tree shrews that were positive for $p21$ than those negative for $p21$ (80.0% vs 11.0%, $P < 0.001$). The incidence of HCC in p21 positive animals in group A was significantly higher than those positive for p21 in group C ($P < 0.05$).

CONCLUSION: A remarkable synergistic effect on HCC development exists between HBV and AFB1. $p53$ mutation promotes the development of HCC. HBV and AFB1 may synergistically induce $p53$ gene mutation, and stimulate ras gene expression. ras gene is activated at the earlier stage during hepatocarcinogenesis. $p21$ protein may be an early marker, and the alterations of $p53$ may be a late event in the development of HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the world's most common cancers and is predominant in Africa and South-east Asia[1]. Epidemiological studies indicated that contamination of food with aflatoxin B1 (AFB1) and chronic infection with hepatitis B virus (HBV) are the major risk factors for human HCC[2,3].

$p53$, a tumor suppressor gene located on the short arm of chromosome 17, normally regulates the activity of the cell cycle machinery. Mutation of the $p53$ gene has been observed with a high prevalence in diverse types of human cancer and frequently occurs with point mutation. The frequencies of $p53$ mutation in HCC from different studies were varied from 18% to 67%[4,5]. Mutation of G to T transversion at the third base of codon 249 of $p53$ gene has been found in human HCC associated with high exposures to AFB1 in Africa and Qidong, China[6,7]. Where this mutation is absent from HCC in the area with negligible exposure to AFB1, the $ras$ gene coding for $M21 000$ protein ($p21$) binds guanine nucleotides and possesses GTPase activity. Through this mechanism, the ras $p21$ participates in the control of cell proliferation, possibly as a signal transducer from cell surface receptors to the nucleus[8]. H-ras oncogene could induce the metastatic phenotype of HCC cell in vivo to enhance its metastatic potential. The mutations of $ras$ genes at codons 12, 13, and 61 leading to the increased expression of normal or mutant form of the $p21$ protein have been observed in human HCC and several other tumors[9]. However, some report that $ras$ proto-oncogene can enhance or inhibit the malignant phenotype in vivo in different systems[10]. In the present study, using tree shrew (Tupaia belangeri chinensis) as an animal model for studying the development of HCC induced by human HBV and/or AFB1, we investigated the alterations of $p53$ and $p21$ during hepatocarcinogenesis in tree shrews.

MATERIALS AND METHODS

Animals

Tree shrews were obtained from Kunming Medical Biology Institute, Chinese Academy of Sciences. One hundred and sixteen adult tree shrews weighed 127±14.5 g. Animals were raised in stainless steel cage individually at room temperature of 25±1 °C and fed with basic diet supplemented with fruits, milk, and eggs. Drinking water was given ad libitum.
HBV sera for infection
Sera positive for HBV surface antigen (HBsAg), e antigen (HBeAg) and antibody against c antigen (anti-HBc) were obtained from several blood donors. The titres of HBeAg and HBeAg were more than 1:1,024. The sera were preserved in a refrigerator at -40 °C and pooled before inoculation.

AFB1
AFB1 was purchased from Sigma Chemical Co., USA. It was dissolved in dimethylsulphoxide (DMSO) and mixed with milk to be sipped by tree shrews.

Reagents
Rabbit polyclonal antibody against human p53 (CM1) and avian-biotin peroxidase complex kit were purchased from Vector Laboratories Inc., USA. RNase mini-kit was purchased from Qiagen Inc., Germany. PCR kit was the product of Stratagene Inc., USA. Rat antibody against human p21 (pan-ras) was purchased from Biosource Inc., USA.

Methods
Blood sample 1 mL was drawn through the femoral veins of each tree shrew before the experiment started. Some tree shrews were inoculated with 0.5 mL of human HBV-infected serum via the femoral vein. Three days later, another 0.5 mL of the same serum was injected peritoneally. After a week, the sera of these animals were checked weekly for HBV infection markers by enzyme-linked immunosorbent assay (ELISA). HBV-infected tree shrews confirmed by ELISA were randomly divided into group A (39 animals) and group B (28 animals). The un-inoculated tree shrews were randomly divided into group C (29 animals) and group D (20 animals). The animals of groups A and C were given AFB1, 200-400 μg/kg b.m. per day, while group D was used as control. Liver biopsies were performed in each group once every 15 wk. The samples of liver biopsy or HCC were cut and the other was kept at -80 °C.

Southern blotting
Three samples of liver biopsy and 5 samples of HCC tissues stored at -80 °C were sent to Korea Research Institute of Bioscience and Biotechnology for Southern blotting to determine the p53 gene status.

Sequencing of p53
Total RNAs were extracted from 10 mg of frozen tumors or biopsied liver tissues. Exon 2-4 (415 bp) of the p53 gene was amplified using the forward primer CDF2: 5′-ATTGGCAGCCA GACTG CCTTCCGGG-3′ and reverse primer CDR4: 5′-CGATT CTAGAGCAAAATCTTGTTGAGGG-3′. Exon 5-11 (974 bp) of the p53 gene was amplified using the forward primer CDF5: 5′-CGATGAAATTCTTGACACACCT ATTGCCA-3′ and reverse primer CDR11: 5′-GTAAGCTTCTGAGCACACCT ATTGCAC-3′. The reactions containing 0.5 μg total RNA, 5 mmol/L MgCl2, 1 mmol/L dNTP, 20 pmoL of each primer, 40 units of RNase inhibitor, 5 units of AMV reverse transcriptase, 5 units of AMV Tag DNA polymerase in a final volume of 50 μL in mRNA selective PCR buffer were used. The mixture of reactants was incubated at 42 °C for 30 min followed by PCR amplification with 25 cycles of at 85 °C for 30 s and at 72 °C for 1 min. PCR products were analyzed on 15 g/L agarose gel containing ethidium bromide. The PCR product of p53 was purified and sequenced by an automatic DNA sequencer.

Immunohistochemistry for p53 and p21
p53 and p21 proteins were detected by immunohistochemical staining using the avdin-biotin complex (ABC) method on the sections of liver tissues and tumors. In brief, formalin-fixed, paraffin-embedded sections were deparaffinized in xylene and were passed through ethanol series. After the endogenous peroxidase activity was blocked, the sections were rinsed in 0.01 mol/L PBS. Non-specific binding was blocked by treatment with 5% normal horse or goat serum for 20 min. Primary antibody was applied to the sections and incubated in a moist chamber overnight at 4 °C. After the sections were washed in 0.01 mol/L PBS, biotinylated horse or goat anti-mouse or rabbit immunoglobulin G was applied and sections were incubated for 50 min at room temperature. After washed, the sections were incubated with avidin-biotin-peroxidase complex for 50 min and then washed again. The chromogen, 3,3'-diaminobenzidine (DAB) was added for 5 to 10 min. Finally, the sections were washed and mounted. The section without primary antibody served as negative control.

Statistical analysis
Differences of HCC incidence and percentages of immunopositivity for p53 and p21 were analyzed by the Chi-square (χ2) test. The difference of the average time for appearance of HCC was analyzed by the Student’s t test.

RESULTS
The first case of HCC appeared at the 83rd wk of the experiment in group B. At that time the number of living animals in groups A, B, C and D were 39, 28, 29 and 20, respectively. After feeding of AFB1 for 105 wk, the amount of AFB1 in groups A and C was 11.6-15.5 mg and 11.4-16.09 mg, respectively. The difference was not statistically significant. The experimental period was 160 wk.

Incidence of HCC
HCC occurred only in groups A, B and C, and the rates of HCC in those groups were 58.9% (23/39), 3.57% (1/28) and 20.68% (6/29), respectively. No HCC was observed in group D. One tree shrew died at the 120th wk in group B had two proliferating pale nodules with 0.5 cm in diameter. They were large proliferating nodules of liver cells under the microscope. Not only was the HCC incidence higher but also the average time for HCC appearance was significantly shorter in group A than that in group C (120±16.6 wk vs 153±8.5 wk, t = 3.336, P < 0.01).

p53 gene
No p53 protein was detected by immunohistochemistry in each group at the 75th wk. The percentages of immunopositivity for p53 in group A (78.6%), B (60%) and C (71.4%) were significantly higher than that in group D (10.0%) at the 105th wk. The positive rates for p53 in HCC samples were not significantly different between groups A and C (52.17%, 12/23 vs 50%, 6/12, P > 0.05). Immunopositive signal of p53 was located in nucleus of cells. The difference of HCC incidence and percentages of immunopositivity for p53 was not statistically significant. The experimental period was 160 wk.

Immunopositive signal of p53 was located in nucleus of cells. The difference of HCC incidence and percentages of immunopositivity for p53 was not statistically significant. The experimental period was 160 wk.
Table 1 Status of p53 gene from liver and tumor tissues of tree shrews

| Animal (Groups) | Treatment | Tissues | Grade of tumors | Status of p53 gene | Change of nucleic acid |
|----------------|-----------|---------|-----------------|-------------------|-----------------------|
| 5201 (C)       | -         | liver   | -               | wt                | -                     |
| 5207 (C)       | -         | tumor   | I               | wt                | -                     |
| 5063 (A)       | +         | tumor   | II              | mt (78)           | GCA-GCG               |
| 5067 (A)       | +         | tumor   | II              | wt                | -                     |
| 5172 (A)       | +         | tumor   | III             | mt (13)           | CCT-CTT               |
| 5173 (A)       | +         | tumor   | II              | mt (275)          | TGT-CGT               |
| 1 (D)          | -         | liver   | -               | wt                | -                     |
| 2 (D)          | -         | liver   | -               | wt                | -                     |

Wt: wild type; mt: mutation.

Table 2 Expression of p21 in normal liver and liver tumor tissues of tree shrews

| Group | No. of animals (n) | incidence of HCC (%) | p21+ | p21- |
|-------|--------------------|-----------------------|------|------|
|       |                    | Animal (n) | Incidence of HCC (%) | Animal (n) | Incidence of HCC (%) |
| A     | 39                 | 23 (58.97)  | 16   | 16 (100.0) |
| B     | 28                 | 1 (3.57)   | 2    | 0     |
| C     | 29                 | 6 (20.68)  | 7    | 4 (54.14) |
| D     | 20                 | 0          | 0    | 0     |

bP<0.01 vs Group C; dP<0.001 vs Group B; eP<0.001, p21+ vs p21- in Group A; fP<0.01, p21+ vs p21- in Group C; gP<0.05 vs Group C in p21+; hP<0.01 vs Group B in p21-.

Table 3 Relationship between p21 expression and HCC development

| Group         | Animal (n) | HCC (n) | Rate of HCC (%) |
|---------------|------------|---------|-----------------|
| p21-positive  | 25         | 20      | 80.00           |
| p21-negative  | 91         | 10      | 10.99           |

bP<0.001 vs p21-negative.

Figure 1 Expression of p53 protein located in nuclei of liver cancer cells (Original magnification: ×400).

p21 protein

p21 protein was located in plasma of liver cells (Figure 2) and overexpressed in totally 16 animals’ liver tissues in group A during hepatocarcinogenesis. All those tree shrews developed HCC. However, only 7 of 23 tree shrews were p21-negative in liver tissues, and developed HCC in the same group at the end of experiment. The incidence of HCC was significantly higher in these p21-positive animals than in those negative ones. There were 2 animals positive for p21 protein in the liver tissues in group B, one of them died at the 120th wk and had 2 proliferating nodules with 0.5 cm in diameter. They were large proliferating nodules of liver cells under microscope. At the end of the experiment, 4 of 7 tree shrews that were positive for p21 developed HCC in Group C, whereas only 2 of 22 tree shrews that were negative for p21 developed HCC in this group. p21 overexpression was not found in group D (Table 2). Totally 25 animals were positive for p21 in liver tissues in all groups and 20 of them developed HCC (80%), while only 10 of totally 91 animals which were negative for p21 developed HCC (10.99%). Only 1 sample of HCC tissue was positive for p21 in all 30 samples of HCC tissues (Table 3).

Figure 2 p21 protein located in plasma of liver cells (Original magnification: ×200).

DISCUSSION

Animals in groups A and B were verified for infection with human HBV[12]. In the present study, not only was the incidence of HCC significantly higher but also the average time for HCC development was shorter in the animals both infected with HBV and exposed to AFB1 than those infected with HBV or exposed to AFB1 alone. These results provided further support for the existence of the synergistic effect between HBV and AFB1 in tree shrew’s hepatocarcinogenesis[13-15]. Even though
only one case of HCC developed in group B, which was infected with HBV alone, proliferation foci and/or nodules appeared quite early and frequently in this group. One tree shrew in group B which died at the 120th wk was found with 2 proliferating nodules with 0.5 cm in diameter in the liver. These results indicate that HBV has the capability of inducing liver cancer, but its capability is weak.

Wild type p53 gene is the control gene at G1 phase of cell cycle. It can inhibit DNA-damaged cell from entering G1 phase and let the cell repair the damage[16]. Mutated p53 gene not only loses the functions that wild type p53 has but also promotes malignant transformation of cells[17]. All the liver tissues of tree shrews in all groups were negative for mutant p53 protein by immunohistochemistry in early period of hepatocarcinogenesis. However, mutant p53 proteins were detectable in the middle stage of hepatocarcinogenesis, before the appearance of HCC. This demonstrates that p53 mutation occurs prior to the appearance of HCC. In the control group, no HCC developed and no mutant p53 proteins and mutations of p53 gene were detected, suggesting that the p53 mutation is a crucial factor to initiate the malignant transformation of cell. The results of examining the status of p53 gene by Southern blotting showed that 2 liver samples biopsied at the 45th wk in group C had an abnormal band of 3.8 kb. This indicates that the alteration of p53 gene in the hepatocyte of tree shrew is dependent on a cumulative amount of AFB1 and sufficient time, and also supports the finding that mutation of p53 occurs before the appearance of HCC. The reason for loss expression of mutant p53 in group A may be due to the low level of mutant p53 protein. In the 8 samples sent to South Korea, p53 mutation was not observed in 3 normal liver tissues, but 3 poorly-differentiated cases from the 5 HCC samples showed p53 mutations. The rate of mutation was consistent with our previous report[18]. It was also similar to the reports on human samples. The 3 tree shrews containing p53 mutation gene were from group A treated by both HBV and AFB1, implying that HBV and AFB1 may play a synergistic role in p53 mutation. This may be one of mechanisms that HBV synergises AFB1 in hepatocarcinogenesis. p53 mutations were located at codons 275, 78 and 13, respectively. No mutation was found at codon 249. It was differently from the mutation at codon 249 of the p53 gene identified as a hotspot mutation in hepatocellular carcinomas occurring in populations exposed to AFB1 and HBV[4,5,9,20]. However, it was similar to the results of studies on non-human primate animal models[21]. This discrepancy may be due to the different species, or too small amount of cases that were detected to find any mutation of p53 at codon 249. Moreover, it also suggests that p53 mutation, which is closely related to the development of HCC, does not merely occur at codon 249.

In HCC ras was first proved as one of the transforming genes, which belong to G-protein family gene. When it is converted to active oncogene by point mutation or gene amplification the signal transmission of cell membranes may change, which drives cell division, and results in abnormal differentiation and finally neoplasm formation. Oncogene ras directly takes part in human carcinogenesis, perhaps accounting for as many as 15-20% of all human tumors. It is well documented that the ras gene product, p21 protein, has GTPase activity and is involved in signal transduction. p21 is now well recognized for its essential function in transducing extracellular signals that regulate cell growth, survival, and differentiation. Overexpression and point mutations of ras gene were not only found in HCC[22-25] but also found in liver cirrhosis and the correlation with liver cell dysplasia[24]. We detected the p21 expression by immunohistochemistry in biopsied liver tissues of tree shrews at the 45th, 105th and 119th wk. The results showed that the accumulative total of positive rate for p21 in group A was 41.02%, which was significantly higher than that in group B (7.14%) and group C (24.13%). This indicates that HBV and AFB1 can synergystically activate ras gene in hepatocyte resulting in overexpression of p21[25]. The p21 protein overexpression appeared before HCC development, indicating that the p21 protein overexpression is the early event during hepatocarcinogenesis and p21 protein may be an early marker in the development of HCC[26]. In the present study, among the 25 animals that were positive for p21, 20 (80%) developed HCC whereas only 10 of 91 (10.99%) p21-negative animals developed HCC at the end of the experiment. This suggests that overexpression of p21 plays an important role in the development of HCC.

Comparison of the nucleotide and amino acid, sequences of human wild-type p53 the structural homology was higher between tree shrews and human than between tree shrews and mouse[11], indicating the tree shrew model is a useful animal model to study the etiology and pathogenesis of HCC in humans[27].

REFERENCES
1. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
2. Wang JS, Huang T, Su J, Liang F, Wei Z, Liang Y, Luo H, Kuang SY, Qian GS, Sun G, He X, Kessler TW, Groopman JD. Hepato-cellular carcinoma and aflatoxin exposure in Zhuqiao village, Fusi County, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 2000; 10: 143-146
3. Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2002; 99: 6655-6660
4. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, Wu Y, Kessler TW, Vogelstein B, Groopman JD. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001; 61: 33-35
5. Shimizu Y, Zhu JJ, Han F, Ishikawa T, Oda H. Different frequencies of p53 codon-249 hot-spot mutations in hepatocellular carcinomas in Jiangsu province of China. Int J Cancer 1999; 82: 187-190
6. Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, Chung FL, Tang MS. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002; 23: 1781-1789
7. Bresac B, Kew M, Wands J, Ozturk M, Selective G to T mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431
8. Wei S, Kito K, Miyoshi A, Matsumoto S, Kauzi A, Aramoto T, Abe Y, Ueda N. Incidence of p53 and ras gene mutations in DMBA-induced rat leukemias. J Exp Clin Cancer Res 2002; 21: 389-396
9. Bello F, Pinchera A, Fugazzaola L, Fontanini G, Elisei R, Rometti C, Pacini F. Expression of p21 ras protein as a prognostic factor of DMBA-induced rat lymphomas. J Exp Clin Cancer Res 2002; 21: 535-539
10. Park US, Su JJ, Ban KC, Qin L, Lee EH, Lee YI. Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and in-take of aflatoxin B(1). Gene 2000; 251: 73-80
11. Yan RQ, Su JJ, Huang DR, Gan YQ, Yang C, Huang GH. Human Hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J Cancer Res Clin Oncol 1996c; 122: 289-295
12. Bannasch P, Khoshkhou NI, Hacker HJ, Radaeva S, Mrozek M, Zillmann U, Kopp-Schneider A, Haberkorn U, Elgas M, Tolle T, Roggendorf M, Toshkov I. Synergistic hepatocarcinogenic effect of hepabnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res 1995; 55: 3318-3330
14 Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003; 23: 405-409

15 Li Y, Su JJ, Qin LL, Yang C, Ban KC, Yan RQ. Synergistic effect of hepatitis B virus and aflatoxin B1 in hepatocarcinogenesis in tree shrews. Ann Acad Med Singapore 1999; 28: 67-71

16 Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N, Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis 2002; 23: 1025-1032

17 Balint EE, Vousden KH. Activation and activities of the p53 tumor suppressor protein. Br J Cancer 2001; 85: 1813-1823

18 Su JJ, Qin GZ, Yan RQ, Huang DR, Yang C, Huang GH, Lotlikar PD. Expression of p53 gene in hepatocellular carcinomas induced by aflatoxin B1 with or without human hepatitis B virus in tree shrews. Exp Mol Med 1997; 29: 177-182

19 Zhu M, Dai Y, Zhan R. HBxAg enhanced p53 protein accumulation in hepatoma cells. Zhonghua Binglixue Zazhi 1999; 28: 31-34

20 Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Santella RM. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57: 3471-3477

21 Rivkina MB, Cullen JM, Robinson WS, Marion PL. State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res 1994; 54: 5430-5437

22 Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k-ras -2 mutations and p16 (INK4A) methylation in hepatocarcinomas in workers exposed to vinyl chloride. Br J Cancer 2001; 84: 982-989

23 Parsons BI, Culp SJ, Manjanatha MG, Heflich RH. Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumour progression. Carcinogenesis 2002; 23: 943-948

24 Feng Z, He R, Lu Z, Ling Y. Expression of ras oncogene p21 product and proliferating cell nuclear antigen in liver cirrhosis and the correlation with liver cell dysplasia. Zhonghua Ganzangbing Zazhi 2000; 8: 343-345

25 Su JJ, Qin GZ, Yan RQ, Huang DR, Yang C, Lotlikar PD. The expression of insulin-like growth factor II, hepatitis B virus X antigen and p21 in experimental hepatocarcinogenesis in tree shrews. Ann Acad Med Singapore 1999; 28: 62-66

26 Fearon ER. K-Ras gene mutation as a pathogenetic and diagnostic marker in human cancer. J Natl Cancer Inst 1993; 85: 1978-1980

27 Cao J, Yang EB, Su JJ, Li Y, Chow P. The tree shrews: adjuncts and alternatives to primates as models for biomedical research. J Med Primatol 2003; 32: 123-130

Edited by Zhu LH and Chen WW  Proofread by Xu FM